Tag Archive for: darolutamide

Phase 2 Trial: Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response via Modulation of Androgen Receptor (SPIDERMAN)

/in , , /by
Read more

European Commission Approves Darolutamide Plus ADT for Metastatic Hormone-Sensitive Prostate Cancer

/in /by

The European Commission has granted marketing authorization to darolutamide (Nubeqa) combined with androgen deprivation therapy (ADT) for treating metastatic hormone-sensitive prostate cancer (mHSPC). This approval, following a positive opinion from the European Medicines Agency in June 2025, allows darolutamide plus ADT to be used with or without docetaxel, offering clinicians greater flexibility in tailoring treatment. […]

Read more

A New Insight From the ARANOTE Trial for mHSPC

/in /by
Read more